×
About 2,580,808 results
Melinta Therapeutics Announces U.S. FDA Approval of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
http://ir.melinta.com/news-releases/news-release-details/melinta-therapeutics-announces-us-fda-approval-supplemental-new

Oct 23rd, 2019 - Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced the U.S. Food and Drug Administration (FDA) has approved BAXDELA® (delafloxacin) for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by designated susceptible b...

Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32317-7/fulltext

Oct 23rd, 2019 - Uncertainty remains about the optimal monotherapy for hypertension, with current guidelines recommending any primary agent among the first-line drug classes thiazide or thiazide-like diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, dihydropyridine calcium channel blockers, and non-dihydropyridine calcium channel blockers, in the absence of comorbid indications...

FDA approves Fiasp® for use in insulin infusion pumps for adults with type 1 or type 2 diabetes
https://www.novonordisk-us.com/media/news-releases.html?122974

Oct 21st, 2019 - Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has expanded the label for Fiasp® (insulin aspart injection) 100 u/mL to include use in insulin infusion pumps for the improvement of glycemic control in adults with type 1 or type 2 diabetes.1 Fiasp®, a rapid-acting insulin, was approved by the FDA in 2017 for use by intravenous infusion under supervision by a health...

2019 Supportive Care: Anxiety, Depression, and Low Social Support Are Significant Factors in Cancer Pain Intensity
https://ascopost.com/news/october-2019/anxiety-depression-and-low-social-support-are-significant-factors-in-cancer-pain-intensity/

Oct 21st, 2019 - Pain is one of the most common symptoms associated with cancer and its treatment, and feelings of anxiety and depression can intensify the level of pain patients experience, according to the results from a study by Galloway et al that will be presented at the 2019 Supportive Care in Oncology Symposium (Abstract 76). However, authors also reported that having greater social support can help miti...

Eton Pharmaceuticals Announces U.S. FDA Approval of Biorphen® (phenylephrine HCI) Injection
https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-announces-us-fda-approval-biorphenr

Oct 21st, 2019 - Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that the U.S. Food and Drug Administration (FDA) has approved Biorphen®, the first and only FDA-approved ready-to-use formulation of phenylephrine for the treatment of clinically important hypotension resulting primarily from vasodilat...

Relief and Prevention of Congestion in Heart Failure Enhance Quality and Length of Life
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.042660
Circulation Drazner, M. et. al.

Oct 20th, 2019 - This article is a commentary on the following Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction

Farxiga approved in the US to reduce the risk of hospitalisation for heart failure in patients with type-2 diabetes
https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2019/farxiga-approved-in-the-us-to-reduce-the-risk-of-hospitalisation-for-heart-failure-in-patients-with-type-2-diabetes-21102019.html

Oct 20th, 2019 - AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Farxiga (dapagliflozin) to reduce the risk of hospitalisation for heart failure (hHF) in adults with type-2 diabetes (T2D) and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors.

Metoprolol for the Prevention of Acute Exacerbations of COPD
https://www.nejm.org/doi/full/10.1056/NEJMoa1908142
The New England Journal of Medicine; Dransfield, M. et. al.

Oct 19th, 2019 - Observational studies suggest that beta-blockers may reduce the risk of exacerbations and death in patients with moderate or severe chronic obstructive pulmonary disease (COPD), but these findings have not been confirmed in randomized trials.

Foamix Receives FDA Approval of AMZEEQ™ Topical Minocycline Treatment for Millions of Moderate to Severe Acne Sufferers
https://www.foamix.com/news-releases/news-release-details/update-foamix-receives-fda-approval-amzeeqtm-topical-minocycline

Oct 17th, 2019 - Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved its novel AMZEEQTM (minocycline) topical foam, 4%. AMZEEQ, formerly known as FMX101, is indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric...

Genentech Announces FDA Approval of Xofluza (Baloxavir Marboxil) for People at High Risk of Developing Influenza-Related Complications
https://www.gene.com/media/press-releases/14817/2019-10-17/genentech-announces-fda-approval-of-xofl

Oct 16th, 2019 - Single-dose Xofluza is the first and only antiviral medicine indicated specifically for patients at high risk of developing serious complications from influenza (flu) The Centers for Disease Control and Prevention (CDC) defines people at high risk of serious flu complications as those who have conditions such as asthma, chronic lung disease, diabetes, heart disease, morbid obesity or adults ...

Non-Small Cell Lung Cancer Treatment (PDQ®) Patient Version
https://www.ncbi.nlm.nih.gov/books/NBK65917/
NIH PDQ Cancer Information Summaries; PDQ Adult Treatment Editorial Board.

Oct 15th, 2019 - This PDQ cancer information summary has current information about the treatment of non-small cell lung cancer. It is meant to inform and help patients, families, and caregivers. It does not give formal guidelines or recommendations for making decisions about health care. NSCLC

Non-Small Cell Lung Cancer Treatment (PDQ®)–Patient Version
https://www.cancer.gov/types/lung/patient/non-small-cell-lung-treatment-pdq
Cancer.gov National Cancer Institute

Oct 15th, 2019 - General Information About Non-Small Cell Lung Cancer NSCLC

U.S. FDA Approves SECUADO® (asenapine) Transdermal System, the First-and-Only Transdermal Patch for the Treatment of Adults with Schizophrenia
http://www.noven.com/PR101519.php

Oct 14th, 2019 - Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced the U.S. Food and Drug Administration (FDA) has approved SECUADO® (asenapine) transdermal system, the first-and-only transdermal patch formulation for the treatment of adults with schizophrenia.1 “As people living with schizophrenia cycle through treatments their therapeutic options ...

Predicting the Risk of Postoperative Pulmonary Complications
https://www.aafp.org/afp/2019/1015/p499.html
American Family Physician;

Oct 14th, 2019 - The incidence of pulmonary complications following major surgery is estimated to be 1% to 23%, with the risk varying based on patient factors and the type of surgery.1 Postoperative pulmonary complications include pneumonia, tracheobronchitis, pulmonary edema, pulmonary embolism, atelectasis, pleural effusion, pneumothorax, bronchospasm, aspiration, respiratory failure, and acute respiratory di...

Influenza Vaccination: Updated Recommendations from ACIP
https://www.aafp.org/afp/2019/1015/p505.html

Oct 14th, 2019 - The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) has released its recommendations for routine influenza vaccination in the 2019–2020 season. Updates this year include the antigenic composition of seasonal influenza vaccines available in the United States and changes related to recent regulatory actions, including labeling changes for previousl...

Nail Changes Following a Viral Infection: Photo Quiz
https://www.aafp.org/afp/2019/1015/p497.html
American Family Physician;

Oct 14th, 2019 - A seven-year-old boy presented with abnormal growth of his fingernails that began two weeks prior. He had no other symptoms, including pain or pruritus on his hands or around his nails. He did not have fevers, chills, nausea, vomiting, or change in activity. He had hand-foot-and-mouth disease two months earlier that was diagnosed based on vesicular lesions in his mouth and on his hands and feet...

Acne Vulgaris: Diagnosis and Treatment
https://www.aafp.org/afp/2019/1015/p475.html
American Family Physician;

Oct 14th, 2019 - Acne vulgaris is the most prevalent chronic skin disease in the United States, affecting nearly 50 million people per year, mostly adolescents and young adults. Potential sequelae of acne, such as scarring, dyspigmentation, and low self-esteem, may result in significant morbidity. Typical acne lesions involve the pilosebaceous follicles and the interrelated processes of sebum production, Cutiba...

The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: New features and the ‘Ten Commandments’ of the 2019 Guidelines are discussed...
https://academic.oup.com/eurheartj/article/40/39/3215/5586545
European Heart Journal; Grant, P. et. al.

Oct 13th, 2019 - The prevalence of diabetes continues to increase, with 60 million thought to have diabetes in Europe in 2017 and predictions of more than 600 million individuals with diabetes worldwide by 2045. These numbers carry a huge burden of morbidity and mortality with a high prevalence of microvascular disease affecting the eyes, nerves, and kidneys and macrovascular disease leading to CV, cerebrovascu...

Coverage from the International Congress of Parkinson’s Disease and Movement Disorders (MDS) 2019
https://www.medscape.com/viewcollection/35073

Oct 8th, 2019 - International Congress of Parkinson’s Disease and Movement Disorders (MDS) 2019: Read clinically focused news coverage of key developments from MDS 2019

ESMO 2019: Overall Survival With Immunotherapy Doublet vs Chemotherapy in Advanced NSCLC
https://ascopost.com/news/october-2019/overall-survival-with-nivolumabipilimumab-vs-chemotherapy-in-advanced-nsclc/

Oct 7th, 2019 - As reported at the European Society for Medical Oncology (ESMO) Congress 2019 (Abstract LBA4) and simultaneously in The New England Journal of Medicine by Matthew D. Hellmann, MD, and colleagues, the phase III CheckMate 227 trial has shown that nivolumab plus ipilimumab improved overall survival vs chemotherapy in patients with advanced non–small cell lung cancer (NSCLC) with programmed cell de...

A Clinician's Guide to Healthy Eating for Cardiovascular Disease Prevention
https://www.acc.org/latest-in-cardiology/articles/2019/10/08/13/20/a-clinicians-guide-to-healthy-eating-for-cvd-prevention

Oct 7th, 2019 - The recently released 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease has given clinicians a comprehensive, evidence-based resource to inform management of patients at increased risk of atherosclerotic cardiovascular disease. In addition to guidance on risk stratification and medication prescribing, the Prevention Guideline stresses the importance of lifestyle interve...

Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease - AMBER
https://www.acc.org/latest-in-cardiology/clinical-trials/2019/10/08/14/26/amber

Oct 7th, 2019 - The AMBER trial showed that the potassium binder patiromer was effective at allowing more patients to remain on spironolactone.

Cannabis and cannabinoids for people with multiple sclerosis
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013444/full

Oct 6th, 2019 - This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess benefit and safety of cannabis‐based medicines, including synthetic, or herbal and plant‐derived cannabinoids, for people with MS.

Genetics of Prostate Cancer (PDQ®)–Health Professional Version
https://www.cancer.gov/types/prostate/hp/prostate-genetics-pdq

Oct 4th, 2019 - This executive summary reviews the topics covered in this PDQ summary on the genetics of prostate cancer, with hyperlinks to detailed sections below that describe the evidence on each topic.

A Comparison of the Efficacy of Enema Solutions in Pediatric Emergency Department Patients
https://www.ncbi.nlm.nih.gov/pubmed/31594739
Journal of Emergency Medicine; Anderson J, et al

Oct 4th, 2019 - Children presenting to pediatric emergency departments (EDs) are frequently given enemas for relief of constipation symptoms; there is very little literature guiding solution selection.

FDA approves Aklief for acne on face, trunk
https://www.healio.com/dermatology/acne/news/online/%7Bcc693b23-e6fc-4919-a303-fc14f62279b4%7D/fda-approves-aklief-for-acne-on-face-trunk

Oct 3rd, 2019 - The FDA recently approved Galderma’s topical retinoid cream, known as Aklief, for the treatment of acne vulgaris. Additionally, the company reported positive safety profiles for Aklief in two phase 3 clinical trials on acne of both the face and trunk in patients aged 9 years and older, according to a news release issued by the company.

Breast Cancer Treatment (Adult) (PDQ®)–Health Professional Version
https://www.cancer.gov/types/breast/hp/breast-treatment-pdq

Oct 3rd, 2019 - Breast cancer is the most common noncutaneous cancer in U.S. women, with an estimated 62,930 cases of in situ disease and 268,600 cases of invasive disease in 2019.[1] Thus, fewer than one of six women diagnosed with breast cancer die of the disease. By comparison, it is estimated that about 66,020 American women will die of lung cancer in 2019. Men account for 1% of breast cancer cases and bre...

Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Niraparib for the Treatment of Metastatic Castration-Resistant Prostate Cancer
https://www.jnj.com/janssen-announces-u-s-fda-breakthrough-therapy-designation-granted-for-niraparib-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer

Oct 2nd, 2019 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for niraparib, an orally-administered poly ADP-ribose polymerase (PARP) inhibitor, for the treatment of patients with BRCA1/2 gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have received prior taxane che...

Seasonal Influenza Vaccination Resources for Health Professionals | CDC
https://www.cdc.gov/flu/professionals/vaccination/index.htm

Oct 2nd, 2019 - CDC Centers for Disease Control and Prevention Influenza Flu - vaccination resources for healh care professionals includes links to ACIP resources, flu vaccine information and patient education materials.

Sleeping less than six hours and heart disease, stroke – deadly combo
https://newsroom.heart.org/news/sleeping-less-than-six-hours-and-heart-disease-stroke-deadly-combo

Oct 1st, 2019 - Middle-aged adults with high blood pressure, Type 2 diabetes, heart disease or stroke could be at increased risk for cancer and early death when sleeping less than 6 hours per day.

Preventive Cardiology as a Subspecialty of Cardiovascular Medicine
http://www.onlinejacc.org/content/74/15/1926?_ga=2.47888103.1317319445.1570642054-675541502.1568116402
Journal of the American College of Cardiology; Shapiro, M. et. al.

Oct 1st, 2019 - Although significant progress has been made to reduce the global burden of cardiovascular disease, efforts have focused primarily on treatment of manifest disease rather than on prevention of events. An enormous opportunity exists to transition focus from intervention to providing equal attention to prevention of cardiovascular disease. The nascent specialty of “preventive cardiology” is emergi...

E-Cigarettes and Vaping-Related Disease
https://www.nejm.org/vaping
New England Journal of Medicine;

Oct 1st, 2019 - The use of e-cigarettes has increased rapidly. Although vaping has been shown to assist with smoking cessation, cases of severe vaping-related pulmonary disease and a number of deaths have recently been reported. Here we present a collection of articles and other resources on e-cigarettes and vaping-related disease, including clinical reports and commentary.

Painful Scrotal Swelling
https://www.aafp.org/afp/2019/1001/p435.html

Sep 30th, 2019 - A 44-year-old man presented with worsening scrotal swelling that began two weeks prior. He also had sharp, constant pain that radiated to both legs (left more than right) and his buttocks. He rated it as 10 out of 10 on a pain scale. The pain worsened with urination and was minimally relieved by over-the-counter ibuprofen. He had never had a similar episode and had no injuries. His sexual histo...

Hand-Foot-and-Mouth Disease: Rapid Evidence Review
https://www.aafp.org/afp/2019/1001/p408.html
American Family Physician; Saguil, A. et. al.

Sep 30th, 2019 - Hand-foot-and-mouth disease is caused by human enteroviruses and coxsackieviruses. Outbreaks can occur in the spring to fall and are common in North America, and most cases occur in patients younger than 10 years. Hand-foot-and-mouth disease is transmitted by fecal-oral, oral-oral, and respiratory droplet contact. Patients present with a low-grade fever, a maculopapular or papulovesicular rash ...

Opioid Use Disorder: Medical Treatment Options
https://www.aafp.org/afp/2019/1001/p416.html
American Family Physician; Coffa, D. et. al.

Sep 30th, 2019 - Opioid use disorder is highly prevalent and can be fatal. At least 2.1 million Americans 12 years and older had opioid use disorder in 2016, and approximately 47,000 Americans died from opioid overdoses in 2017. Opioid use disorder is a chronic relapsing condition, the treatment of which falls within the scope of practice of family physicians. With appropriate medication-assisted treatment, pat...

Anticoagulation: Updated Guidelines for Outpatient Management
https://www.aafp.org/afp/2019/1001/p426.html
American Family Physician;

Sep 30th, 2019 - Anticoagulation therapy is recommended for preventing, treating, and reducing the recurrence of venous thromboembolism, and preventing stroke in persons with atrial fibrillation. Direct oral anticoagulants are first-line agents for eligible patients for treating venous thromboembolism and preventing stroke in those with nonvalvular atrial fibrillation. Vitamin K antagonists are recommended for ...

Protecting Patients from Elder Abuse Scams
https://www.aafp.org/afp/2019/1001/p438.html
American Family Physician;

Sep 30th, 2019 - Living on my own continues to be very important to me, even though I'm getting older and am sometimes forgetful. I manage pretty well with the help of my son, who visits me weekly, and my family doctor, who I see monthly for my hypertension, stomach reflux problems, prediabetes, and high cholesterol. I try to manage my forgetfulness with the help of a pill box so that I remember to take my medi...

Global Initiative for Asthma: Global Strategy for Asthma Management & Prevention
https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf

Sep 29th, 2019 - The 2019 update of the Global Strategy for Asthma Management and Prevention incorporates new scientific information about asthma based on a review of recent scientific literature by an international panel of experts on the GINA Science Committee. This comprehensive and practical resource about one of the most common chronic lung diseases worldwide contains extensive citations from the scientifi...

U.S. FDA Approves INVOKANA® (canagliflozin) to Treat Diabetic Kidney Disease (DKD) and Reduce the Risk of Hospitalization for Heart Failure in Patients with Type 2 Diabetes (T2D) and DKD
https://www.janssen.com/us-fda-approves-invokana-canagliflozin-treat-diabetic-kidney-disease-dkd-and-reduce-risk

Sep 29th, 2019 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved a new indication for INVOKANA® (canagliflozin) to reduce the risk of end-stage kidney disease (ESKD), worsening of kidney function, cardiovascular (CV) death, and hospitalization for heart failure in adults with type 2 diabetes and diabetic kidney disease (nephropa...

Alcohol and “Deaths of Despair”
https://www.spectrum.niaaa.nih.gov/features/features-01.html
NIAAA Spectrum;

Sep 29th, 2019 - In 2015, Princeton University economists Anne Case, Ph.D., and Angus Deaton, Ph.D., reported something unexpected. After decreasing since the end of World War II, rates of death began to increase in the United States for people in some groups. The rise in deaths was driven primarily by drug and alcohol overdoses, suicides, and liver disease. These conditions, in turn, were related to declining ...

Medical education needs to stop burning out students — now
https://www.statnews.com/2019/08/29/medical-education-stop-burning-out-students/

Sep 28th, 2019 - Students’ time in medical school should help them grow and become insightful, caring doctors. Instead, medical education is somehow turning smart, gifted, enthusiastic applicants into exhausted and unhappy students who become interns, residents, and physicians at increased risk of depression and burnout.

Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease
https://www.nejm.org/doi/full/10.1056/NEJMoa1909406

Sep 27th, 2019 - BACKGROUND Long-term outcomes after percutaneous coronary intervention (PCI) with contemporary drug-eluting stents, as compared with coronary-artery bypass grafting (CABG), in patients with left main coronary artery disease are not clearly established. METHODS We randomly assigned 1905 patients with left main coronary artery disease of low or intermediate anatomical complexity (according t...

Can Mild Asthma Be Managed with Only As-Needed Inhaled Steroids Plus a Bronchodilator?
https://www.jwatch.org/na49830/2019/09/26/can-mild-asthma-be-managed-with-only-needed-inhaled

Sep 25th, 2019 - David J. Amrol, MD reviewing Hardy J et al. Lancet 2019 Sep 14 Gauthier M and Wenzel SE. Lancet 2019 Sep 14

FDA Approves Abbott’s "Low Dose," Recharge-Free Spinal Cord Stimulation System with up to Ten Year Battery Life for People Living with Chronic Pain
https://www.multivu.com/players/English/8608451-abbott-proclaim-xr-spinal-cord-stimulation-system/

Sep 25th, 2019 - Proclaim XR neurostimulation system uses Abbott’s proprietary, low energy BurstDR™ therapy coupled with the BoldXR™ low dosing protocol for safe, effective pain relief and a battery that lasts up to 10 Years*

International Congress of Parkinson’s Disease and Movement Disorders Final Program
https://www.mdscongress.org/Congress-Branded/19FP-_blue_puzzle_online.pdf

Sep 25th, 2019 - On behalf of the International Parkinson and Movement Disorder Society (MDS), we are pleased to welcome you to the International Congress of Parkinson’s Disease and Movement Disorders. Nice is a charming, picturesque city nestled on the southeast coast of France at the foot of the Alps and extending along the Mediterranean Sea. In addition to the draw of the dynamic landscape, including the ...

Screening and Management of the Hyperandrogenic Adolescent
https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Adolescent-Health-Care/Screening-and-Management-of-the-Hyperandrogenic-Adolescent

Sep 23rd, 2019 - Although androgen excess can manifest in many ways, the most common and recognizable symptoms are hirsutism and acne. Reports of hirsutism and acne should be taken seriously because of their possible association with medical disorders, their substantial effect on self-esteem and quality of life, and the potential for psychosocial morbidity. In patients with symptoms of androgen excess, the diff...

Are Antihistamines and Steroids Helpful for Anaphylaxis?
https://www.jwatch.org/na49921/2019/09/24/are-antihistamines-and-steroids-helpful-anaphylaxis

Sep 23rd, 2019 - David J. Amrol, MD reviewing Gabrielli S et al. J Allergy Clin Immunol Pract 2019 Sep/Oct

Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline
https://annals.org/aim/fullarticle/2751913/prevention-diagnosis-evaluation-treatment-hepatitis-c-virus-infection-chronic-kidney

Sep 23rd, 2019 - Description: The Kidney Disease: Improving Global Outcomes (KDIGO) 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C virus (HCV) infection in chronic kidney disease (CKD) is an extensive update of KDIGO's 2008 guideline on HCV infection in CKD. This update reflects the major advances since the introduction of direct-acting antivirals (DAAs...

Sjögren’s Syndrome in Systemic Lupus Erythematosus - a Subset Characterized by a Systemic Inflammatory State
http://www.jrheum.org/content/early/2019/09/11/jrheum.190250
J Rheumatology; Ruacho G, et al

Sep 20th, 2019 - Secondary Sjögren’s syndrome (SLE-sSS) is an often-neglected subset of patients with Systemic lupus erythematosus (SLE). Furthermore, primary Sjögren’s syndrome overlaps and can be difficult to delineate from SLE. To shed light on the SLE-sSS subset, we investigated a large and well-characterized SLE cohort comparing patients with SLE-sSS versus SLE patients without SS (SLE-nonsSS) and controls.

FDA approves Rybelsus® (semaglutide), the first GLP-1 analog treatment available in a pill for adults with type 2 diabetes
https://www.novonordisk-us.com/media/news-releases.html?122973

Sep 19th, 2019 - Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved Rybelsus® (semaglutide) tablets 7 mg or 14 mg for adults with type 2 diabetes that along with diet and exercise may improve blood sugar (glucose).1 Rybelsus® is the first and only glucagon-like peptide-1 (GLP-1) analog in a pill and a new option for adults with type 2 diabetes who are not achieving their ...